09 December 2024 : Clinical Research
Shiga Toxin-Producing E. coli and Hemolytic Uremic Syndrome: A Study of the 2022 Outbreak in Turkey
Oğuzhan Zengin
1ABCDEFG*, Burak Göre 1ABCDEFG, Oğuz Öztürk 2ABCDEFG, Muhammet Göv 1ABCDEFG, Enes Seyda Şahiner 1ABCDEFG, Osman İnan 1ABCDEFG, Emra Asfuroğlu Kalkan 1ABCDEFG, Şimal Kösal Cevher 3ABCDEFG, Ahmet Kürşad Güneş 4ABCDEFG, Gülsüm Özet 5ABCDEFG, İhsan Ateş 1ABCDEFG
DOI: 10.12659/MSM.946033
Med Sci Monit 2024; 30:e946033
Table 1 Evaluation of demographic characteristics, treatments, and extrarenal findings at admission.
| Age | 55 (22–81) |
| Male | 4 (19.05%) |
| Female | 17 (80.95%) |
| Oliguria | 16 (76.1%) |
| Hemorrhagic diarrhea | 10 (47.6%) |
| Total length of hospital stay | 20.71±11.49 17 (2–56) |
| Eculizumab | 4 (19.05%) |
| Plasmapheresis | 7 (33.33%) |
| Hemodialysis | 10 (47.67%) |
| Antibiotic | 8 (38.10%) |
| Cardiogenic involvement | 1 (4.76%) |
| Neurogenic involvement | 5 (23.81%) |
| Abdominal involvement | 21 (100.00%) |
| Pulmonary involvement | 19 (90.48%) |